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Abstract 
Anti-TNF-α agents are currently utilised for the treatment of a vast array of autoimmune 
conditions including inflammatory bowel disease, rheumatoid arthritis, ankylosing 
spondylitis and psoriasis. It is however noted that such therapeutic strategies have been 
linked to the specific induction of cutaneous-based reactions such as dermatitis, 
erythema multiforme and psoriasis. Here we present the case of a young female patient 
with Crohn’s disease who developed psoriasis following treatment with the anti-TNF-α 
drug adalimumab and highlight the possible pathogenetic mechanisms involved in such 
an occurrence. 
 
Case Presentation 
A 20-year-old female with extensive terminal ileal and colonic Crohn’s disease was initially 
successfully managed on a drug regimen of prednisolone and mesalazine which helped to induce 
remission. The patient unfortunately however developed a mesalazine-induced aplastic anaemia. This 
subsequently resolved with blood product support and withdrawal of this therapy. Her thiopurine 
methyl transferase levels were normal, so she was commenced on azathioprine. This maintained her 
disease remission but was associated with neutropenic sepsis, necessitating the withdrawal of the 
thiopurine therapy with subsequent clinical and endoscopic disease flare. Induction and maintenance 
infliximab was used to regain remission. This required an infusion dose and frequency escalation to 
maintain clinical response. After 58 weeks of infliximab therapy, the patient was requiring 10 mg/kg 6 
times weekly and hence was transferred to the fully human anti-TNF-α injection adalimumab for loss of 
response to infliximab. Initially this strategy regained disease control, but due to relapse at 40 mg every 
other week, the dose was increased step-wise to 80 mg weekly which fortunately maintained remission. 
During her treatment with adalimumab the presence of purple-coloured plaque-like lesions 
primarily on her abdomen were noted (fig. 1).  
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What Is the Diagnosis? 
Figure 1 demonstrates the presence of psoriasis which is presumed to be a result of 
treatment with adalimumab. 
TNF-α has been identified as a key cytokine in the pro-inflammatory pathways that 
drive diseases such as inflammatory bowel disease and rheumatoid arthritis [1]. Anti-
TNF-α agents such as infliximab and adalimumab are widely used in the treatment of 
these conditions and have been shown to have an impact on pro-inflammatory and 
apoptotic pathways. They are also effective in the treatment of the dermatological and 
rheumatological manifestations of psoriasis [2]. However, there have been a number of 
cases reported where such agents may be responsible for new onset or worsening of 
psoriasis. A study of 126 patients who underwent treatment with anti-TNF-α inhibitors 
demonstrated evidence of psoriasis in 76 individuals, palmoplantar pustular psoriasis in 
37 cases and psoriasis of the nails in 6 cases [3]. There is mounting evidence that a key 
innate immune pathway for triggering common human autoimmune diseases, including 
psoriasis, involves plasmacytoid dendritic cell precursors and type 1 interferon (IFN) 
production. A recent study involving immunohistochemical staining of skin biopsy 
specimens for myxovirus-resistance protein A (MxA, a surrogate marker for lesional type 
1 IFN activity) demonstrated increased staining in TNF-α inhibitor-induced psoriasis 
compared with psoriasis vulgaris [4]. Research suggests that a psoriasiform eruption 
during anti-TNF-α treatment seems to be a class effect without any confirmed 
predisposing factors and does not specifically require treatment discontinuation [5]. 
Further studies are however needed to determine the exact mechanism of and appropriate 
treatment for anti-TNF-α-induced psoriasis. 
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Fig. 1. Presence of psoriasis which is presumed to be a result of treatment with adalimumab. 
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